

FOR THE FINANCIAL PERIOD ENDED 31 March 2017

ANNOUNCEMENT

The Board of Directors of Malaysian Genomics Resource Centre Berhad (hereinafter referred to as "MGRC" or "the Company") and its subsidiaries ("the Group") hereby announce the following unaudited results for the third quarter ended 31 March 2017.

A PRESENTATION OF RESULTS

I CONDENSED STATEMENT OF PROFIT AND LOSS AND OTHER COMPREHENSIVE INCOME

	3rd C	Quarter	Year-to-Date	
	Current Year	Previous Year	Current Year	Previous Year
for the financial period ended	31.3.2017	31.3.2016	31.3.2017	31.3.2016
	(RM'000)	(RM'000)	(RM'000)	(RM'000)
Revenue	1,627	1,788	6,960	8,581
Other Income	42	5	135	9
Marketing and distribution	(12)	(58)	(259)	(329)
Employee benefits and expense	(630)	(618)	(2,484)	, ,
Depreciation and amortisation	(207)	(227)	(640)	
Lab consumables	(285)	` '	(687)	, ,
Lab contract services	(115)	-	(740)	, ,
Exclusive license fee	-	(62)	-	(186)
System maintenance cost	-	173	-	(429)
Administrative expenses	(664)	(588)	(2,025)	(1,907)
Profit / (loss) from operations	(244)	126	260	1,463
Share of profits / (loss) of a joint venture	150	103	18	162
Profit / (loss) before tax	(94)	229	278	1,625
Income tax expenses	(10)	(1)	(24)	(2)
Profit / (loss), net of tax, representing total comprehensive income	(104)	228	254	1,623
Profit / (loss) attributable to:			-	
Owners of the parent	(104)	228	254	1,623
Net profit / (loss) for the period	(104)	228	254	1,623
Earnings / (Loss) per share (EPS) attributable to the equity holders of the Company (sen)				
Basic EPS	(0.10)		0.25	1.72
Diluted EPS	N/A	N/A	N/A	N/A

The unaudited condensed statement of profit and loss and other comprehensive income should be read in conjunction with the audited financial statements for the financial year ended 30 June 2016 and the accompanying explanatory notes that form an integral part of the Interim Financial Statements.

Notes:-

There is no income/expense in relation to other income including investment income, interest expense, provision for/write-off of receivables, provision for/write-off of inventories, gain/loss on disposal of quoted or unquoted investments or properties, foreign exchange gain/loss, impairment of assets, gain/loss on derivatives, or exceptional items.

N/A - Not Applicable



FOR THE FINANCIAL PERIOD ENDED 31 March 2017

A PRESENTATION OF RESULTS (cont.)

II CONDENSED STATEMENT OF FINANCIAL POSITION

	21 2 2017	30.6.2016
as at	31.3.2017 (RM'000)	(RM'000)
	, , , ,	
ASSETS		
NON-CURRENT ASSETS		
Plant and equipment	483	527
Intangible assets	1,324	1,782
Investment in a joint venture	9,920	9,902
CURRENT ASSETS		
Trade and other receivables	4,303	3,993
Inventories	904	1,169
Other current assets	33	19
Tax recoverable	28	25
Cash and bank balances	7,941	4,047
TOTAL ASSETS	24,936	21,464
EQUITY AND LIABILITIES		
EQUITY ATTRIBUTABLE TO OWNERS OF THE PARENT		
Share capital	10,351	9,410
Share premium	18,138	14,755
Other reserve	(1,682)	(1,682)
(Accumulated losses)/Retained earnings	(2,840)	(3,094)
TOTAL EQUITY	23,967	19,389
CURRENT LIABILITIES		
Trade and other payables	969	2,075
TOTAL LIABILITIES	969	2,075
TOTAL EQUITY AND LIABILITIES	24,936	21,464
Net assets (RM'000)	23,967	19,389
Net assets per share attributable to equity holders of the Company (sen)	23.15	20.60

The unaudited condensed statement of financial position should be read in conjunction with the audited financial statements for the financial year ended 30 June 2016 and the accompanying explanatory notes that form an integral part of the Interim Financial Statements.



FOR THE FINANCIAL PERIOD ENDED 31 March 2017

A PRESENTATION OF RESULTS (cont.)

III CONDENSED STATEMENT OF CHANGES IN EQUITY

		← N	on-Distributab	le →	Distributable
	Equity, Total	Share Capital	Share Premium	Other reserve	Retained Earnings / (Accumulated Losses)
for the financial year ended 30 June 2016	(RM'000)	(RM'000)	(RM'000)	(RM'000)	(RM'000)
Opening halance at 1 July 2015	17,652	9,410	14,755	(1,682)	(4 921)
Opening balance at 1 July 2015	•	•	14,755	(1,002)	(4,831)
Total comprehensive income / (loss)	1,737	-	-	-	1,737
Closing balance at 30 June 2016	19,389	9,410	14,755	(1,682)	(3,094)
for the financial period ended 31 March 2017	(RM'000)	(RM'000)	(RM'000)	(RM'000)	(RM'000)
Opening balance at 1 July 2016	19,389	9,410	14,755	(1,682)	(3,094)
Total comprehensive income / (loss)	254	-		(2,002)	254
Issuance of new shares	4,324	941	3,383	-	-
Closing balance at 31 March 2017	23,967	10,351	18,138	(1,682)	(2,840)

The unaudited condensed statement of changes in equity should be read in conjunction with the audited financial statements for the financial year ended 30 June 2016 and the accompanying explanatory notes that form an integral part of the Interim Financial Statements.



FOR THE FINANCIAL PERIOD ENDED 31 March 2017

A PRESENTATION OF RESULTS (cont.)

IV CONDENSED STATEMENT OF CASH FLOWS

	Year-to-Date		
	Current Year	Previous Year	
for the financial period ended	31.3.2017	31.3.2016	
	(RM'000)	(RM'000)	
Cash flows from operating activities			
Profit / (loss) before tax	278	1,625	
Adjustments for:			
Share of loss/(profits) of a joint venture	(18)	(162)	
Amortisation of intangible assets	458	458	
Depreciation of plant and equipment	182	250	
Gain on disposal of plant and equipment	(37)	-	
Interest income	(98)	(9)	
Operating profit / (loss) before working capital changes	765	2,162	
(Increase) / decrease in receivables	(324)	(3,319)	
(Increase) / decrease in inventories	265	(157)	
(Decrease) / increase in payables	(1,106)	1,373	
Cash (used in) / generated from operations	(400)	59	
Tax refund/(paid)	(27)	(23)	
Net cash (used in) / generated from operating activities	(427)	36	
Cash flows from investing activities			
Interest received	98	9	
Proceeds from disposal of plant and equipment	37	-	
Purchase of plant and equipment	(138)	(167)	
Dividend from a joint venture	-	221	
Net cash (used in) / generated from investing activities	(3)	63	
Cash flows from financing activities			
Proceeds from issuance of shares	4,324	-	
Net cash generated from / (used in) financing activities	4,324	-	
Net (decrease) / increase in cash and cash equivalents	3,894	99	
Cash and cash equivalents at beginning of the period	4,047	295	
Cash and cash equivalents at end of period	7,941	394	

The unaudited condensed statement of cash flows should be read in conjunction with the audited financial statements for the financial year ended 30 June 2016 and the accompanying explanatory notes that form an integral part of the Interim Financial Statements.



FOR THE FINANCIAL PERIOD ENDED 31 March 2017

UNAUDITED NOTES TO THE INTERIM FINANCIAL STATEMENTS

B Explanatory Notes Pursuant to MFRS 134

i Basis of Preparation & Changes in Accounting Policies

These condensed consolidated interim financial statements have been prepared in accordance with MFRS 134 Interim Financial Reporting, and Rule 9.22 and Appendix 9B of the ACE Market Listing Requirements ("Listing Requirements") of Bursa Malaysia Securities Berhad ("Bursa Malaysia").

This report should be read in conjunction with the audited financial statements for the financial year ended 30 June 2016 and the accompanying explanatory notes. The significant accounting policies adopted in preparing these condensed consolidated interim financial statements are consistent with those of the audited financial statements for the financial year ended 30 June 2016.

Details of standards, amendments to published standards and interpretations to existing standards that are applicable to the Group with effect from 1 January 2016 or later are provided in the notes to the audited financial statements of the Group for the financial year ended 30 June 2016.

ii Auditors' Report on Preceding Annual Financial Statements

The audited financial statements for the financial year ended 30 June 2016 were not qualified.

iii Seasonal and Cyclical Factors

The operations of MGRC were not significantly affected by seasonal and cyclical factors.

iv Material and Unusual Items Affecting Assets, Liabilities, Equity, Net Income or Cash Flow

There were no material and unusual items affecting assets, liabilities, equity, net income or cash flows during the financial period.

v Material Changes in Estimates

There were no material changes in the estimates that had effect(s) on the financial period.

vi Debt and Equity Securities

There were no issues, repurchases and repayments of debt and equity securities for the financial period to date.

vii Dividends Paid

There were no dividends paid for the financial period.



FOR THE FINANCIAL PERIOD ENDED
31 March 2017

B Explanatory Notes Pursuant to MFRS 134 (cont.)

viii Segmental Information

FRS 8 requires identification of reporting segment on the basis of internal reports that are regularly reviewed by the entity's Chief Operating Decision Maker in order to allocate resources to the segment and assess its performance. The management monitors the operating results of the Group as a whole for the purpose of making decisions about resource allocation and performance assessment. Accordingly, the Group has only one reportable segment for the period under review as well as the forseeable future. Please refer to the financial statements presented in Part A of this announcement.

ix Valuation of Plant and Equipment

There has been no valuation made on any of the Group's plant and equipment during the current financial period under review.

x Subsequent Events

There were no material events subsequent to the end of the current financial period under review that have not been reflected.

xi Changes in the Composition of the Group

There were no changes in the composition of the Group, including business combinations, acquisition or disposal of subsidiaries and long-term investments, restructuring and discontinuing operations for the financial period to date, except for as disclosed in the Status of Corporate Proposal note (in part C note vi).

xii Contingent Liabilities or Contingent Assets

There was no contingent liability or contingent asset arising since the last audited annual statement of financial position date as at 30 June 2016.

xiii Capital Commitments

There were no material capital commitments for the purchase of property, plant and equipment that were not provided for in the interim financial statements as at the end of the financial period.



FOR THE FINANCIAL PERIOD ENDED 31 March 2017

B Explanatory Notes Pursuant to MFRS 134 (cont.)

xiv Related Party Transactions

Save as disclosed below, there were no significant related party transactions during the financial period to date:-

a)	Significant Related Par	ty Transactions	3rd Quarter		Year-to-Date	
			Current Year	Previous Year	Current Year	Previous Year
	for the financial period en	ided	31.3.2017	31.3.2016	31.3.2017	31.3.2016
	Related Party	Nature of Transaction	(RM'000)	(RM'000)	(RM'000)	(RM'000)
	Neuramatix, our ultimate holding company	Management fee payable to Neuramatix pursuant to Shared Services Agreement.	288	231	565	733
	Synamatix, our holding company	Exclusive licence fees payable to Synamatix with respect of software developed by Synamatix pursuant to Software License Agreement.	-	62	-	186
	Synamatix, our holding company	System maintenance fees payable to Synamatix for annual maintenance of licensed software pursuant to Software License Agreement.	-	(173)	-	429
			288	120	565	1,348
b)	Compensation of Key M	Management Personnel (excl	uding directo	rs)		
	Salaries, allowances and be	onuses	138	222	444	673
	Contributions to defined c	ontribution plan	17	17	53	49
					497	722

xv Cash and Cash Equivalents

	Current Year	Previous Year
as at	31.3.2017	
	(RM'000)	(RM'000)
Cash on hand and at banks	91	42
Deposits with licensed banks	7,850	352
	7,941	394

xvi Inventories

There was no write-down of inventories during the financial period to date.



FOR THE FINANCIAL PERIOD ENDED 31 March 2017

C Explanatory Notes Pursuant to Appendix 9B, of the Listing Requirements

These condensed consolidated interim financial statements, for the financial period ended 31 March 2017, have been prepared in accordance with Rule 9.22 and Appendix 9B of the Listing Requirements.

i Performance of the Group

Current Year 3rd Quarter versus Previous Year 3rd Quarter

For the third quarter ended 31 March 2017, the Group recorded a revenue of RM1.6 million, which represents a reduction of RM0.2 million as compared to a revenue of RM1.8 million for the third quarter in the preceding year.

For the current quarter, the Group recorded a loss before tax of RM0.1 million as compared to a profit before tax of RM0.2 million in the same quarter of the preceding year.

The loss before tax was mainly due to lower revenue (RM1.6 million for the third quarter ended 31 March 2017 as compared to RM1.8 million for the third quarter in the preceding year).

Current Year-to-Date versus Previous Year-to-Date

The Group recorded a revenue of RM7 million, which represents a reduction of RM1.6 million as compared to a revenue of RM8.6 million in the previous year-to-date.

The Group registered a profit before tax of RM0.3 million as compared to a profit before tax of RM1.6 million in the corresponding period of the preceding year. A lower profit was achieved mainly due to lower revenue recognised.

ii Comparison with Preceding Quarter's Results

The comparison of this quarter's results with the preceding quarter is set out below.

	Current Quarter	Preceding Quarter	Variance
for the financial period ended	31.3.2017 (RM'000)	31.12.2016 (RM'000)	(RM'000)
Revenue Profit / (loss) before tax	1,627 (94)	2,046 (463)	(419) 369

A lower loss before tax was recorded compared to the preceding quarter despite lower revenue (RM1.6 million) recognised in the current period as compared to RM2 million, due to lower costs incurred for marketing and distribution and employee benefits and expenses.

iii Prospects of the Group

We are improving our distribution channels for better customer reach. We remain committed in our continuous efforts to expand our customer base.



FOR THE FINANCIAL PERIOD ENDED 31 March 2017

C Explanatory Notes Pursuant to Appendix 9B, of the Listing Requirements (cont.)

iv Variance from Profit Forecast

The Group did not publish any profit forecast.

v Taxation

MGRC's BioNexus pioneer status accords the Company with tax exemption on its statutory income for qualifying activities. The Group's effective tax rate for the current financial year is thus lower than the Malaysian statutory tax rate of 25%.

Taxation	3rd C	3rd Quarter Year-to-Da		to-Date
	Current Year	Previous Year	Current Year	Previous Year
for the financial period ended	31.3.2017	31.3.2016	31.3.2017	31.3.2016
	(RM'000)	(RM'000)	(RM'000)	(RM'000)
Malaysian income tax:				
Current period	10	1	24	2
Prior period	-	-	-	-
Total	10	1	24	2

The above tax has arisen in relation to interest income.

vi Status of Corporate Proposal

There is no corporate proposal announced but not completed as at the date of this announcement except for as announced earlier that MGRC, had on 27 April 2017, entered into a conditional share sale agreement SSA") with Ajmaks Sdn Bhd ("Ajmaks" or "Vendor") for the proposed acquisition of 49,000 ordinary shares and 8,993,500 redeemable convertible preference shares ("RCPS") of MPath Sdn Bhd ("MPath") held by Ajmaks, representing 50% equity interest in MPath for a total purchase consideration of RM11.50 million ("Purchase Consideration") ("Proposed Acquisition").

vii Borrowings

The Group does not have any borrowings as at 31 March 2017.

viii Material Litigations

As at the date of this announcement, there are no material litigations against the Group or taken by the Group.

ix Dividends

No dividends were declared during the current financial period under review.

MALAYSIAN GENOMICS RESOURCE CENTRE BERHAD



FOR THE FINANCIAL PERIOD ENDED 31 March 2017

C Explanatory Notes Pursuant to Appendix 9B, of the Listing Requirements (cont.)

x Utilisation of Proceeds

Private placement

On 17 October 2016, the Board of Directors of MGRC announced that the Company proposes to undertake the private placement of new ordinary shares of RM0.10 each in MGRC, representing not more than ten percent (10%) of the issued and paid-up share capital of MGRC ("Private Placement").

The Private Placement has been completed on 8 November 2016 following the listing of and quotation for 9,410,000 new MGRC Shares on the ACE Market of Bursa Securities at an issue price of RM0.48 which raised a total proceeds of approximately RM4.52 million.

The status of the utilisation of proceeds from the Private Placement is as follows:-

Utilisation of Proceeds Purpose Details (if available)	Intended Timeframe for Utilisation	Proposed Utilisation (RM'000)	Actual Utilisation (RM'000)	Balance of Amo	ount Allocated (%)
		•			
Development and business expansion	Within 12 months	4,317	-	4,317	100%
Private placement expenses*	Within 1 month	200	193	7	4%
Total	- -	4,517	193	4,324	

^{*} The Board of Directors has approved to utilise the excess of the amount allocated for private placement expenses as working capital.

xi EPS

a) **Basic EPS** Computed by dividing the profit / (loss), net of tax, attributable to owners of the parent for the financial period by the weighted average of the number of ordinary shares in issue during the period.

Basic EPS	3rd Quarter Year-to-Dat		to-Date	
	Current Year	Previous Year	Current Year	Previous Year
for the financial period ended	31.3.2017	31.3.2016	31.3.2017	31.3.2016
Profit / (loss), net of tax, attributable to owners of the parent (RM'000) Weighted average number of ordinary shares of RM0.10 each	(104)	228	254	1,623
issue ('000)	103,510	94,100	103,510	94,100
Basic EPS (sen)	(0.10)	0.24	0.25	1.72

b) **Diluted EPS** The Group does not have any convertible shares or convertible financial instruments for the current financial quarter and financial period to date.



FOR THE FINANCIAL PERIOD ENDED 31 March 2017

xii Disclosure of Realised and Unrealised Profits / (Losses)

as at	31.3.2017 (RM'000)	30.6.2016 (RM'000)
Realised accumulated losses of the Company	(5,359)	(5,599)
Realised accumulated losses of a subsidiary	(42)	(38)
Total share of retained profit from a joint venture:		
Realised	2,742	2,724
Unrealised	(181)	(181)
Group accumulated losses	(2,840)	(3,094)

xiii Authorisation for Issue

The interim financial statements were authorised for issue by the Board of Directors of MGRC in accordance with a Resolution of the Directors dated 11 May 2017.